[go: up one dir, main page]

SV2010003598A - Derivados de tiazol usados como inhibidores de pi 3-cinasa - Google Patents

Derivados de tiazol usados como inhibidores de pi 3-cinasa

Info

Publication number
SV2010003598A
SV2010003598A SV2010003598A SV2010003598A SV2010003598A SV 2010003598 A SV2010003598 A SV 2010003598A SV 2010003598 A SV2010003598 A SV 2010003598A SV 2010003598 A SV2010003598 A SV 2010003598A SV 2010003598 A SV2010003598 A SV 2010003598A
Authority
SV
El Salvador
Prior art keywords
derivatives used
cinasa
inhibitors
tiazol
tiazol derivatives
Prior art date
Application number
SV2010003598A
Other languages
English (en)
Inventor
Giorgio Caravatti
Robin Alec Fairhurst
Pascal Furet
Vito Guagnano
Patricia Imbach
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SV2010003598A publication Critical patent/SV2010003598A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

COMPUESTOS DE LA FORMULA (I); Y SUS SALES, EN DONDE LOS SUSTITUYENTES SON COMO LOS DEFINIDOS EN LA DESCRIPCIÓN; A COMPOSICIONES Y USO DE LOS COMPUESTOS EN EL TRATAMIENTO DE ENFERMEDADES MEJORADAS POR LA INHIBICIÓN DE LA FOSFADITILINOSITOL 3-CINASA
SV2010003598A 2007-12-20 2010-06-18 Derivados de tiazol usados como inhibidores de pi 3-cinasa SV2010003598A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07150228 2007-12-20

Publications (1)

Publication Number Publication Date
SV2010003598A true SV2010003598A (es) 2011-03-23

Family

ID=39273277

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2010003598A SV2010003598A (es) 2007-12-20 2010-06-18 Derivados de tiazol usados como inhibidores de pi 3-cinasa

Country Status (28)

Country Link
US (1) US8940771B2 (es)
EP (1) EP2240475B1 (es)
JP (1) JP2011506560A (es)
KR (1) KR20100093129A (es)
CN (1) CN101952282A (es)
AR (1) AR069798A1 (es)
AU (1) AU2008340053A1 (es)
BR (1) BRPI0820722A2 (es)
CA (1) CA2710122A1 (es)
CL (1) CL2008003822A1 (es)
CO (1) CO6321276A2 (es)
CR (1) CR11491A (es)
DO (1) DOP2010000183A (es)
EA (1) EA201000947A1 (es)
EC (1) ECSP10010271A (es)
ES (1) ES2437595T3 (es)
IL (1) IL206286A0 (es)
MA (1) MA31903B1 (es)
NI (1) NI201000107A (es)
PA (1) PA8809001A1 (es)
PE (1) PE20091523A1 (es)
SM (1) SMP201000096B (es)
SV (1) SV2010003598A (es)
TN (1) TN2010000293A1 (es)
TW (1) TW200930364A (es)
UY (1) UY31545A1 (es)
WO (1) WO2009080694A1 (es)
ZA (1) ZA201003928B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR044519A1 (es) * 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
NZ582485A (en) 2007-07-17 2012-05-25 Rigel Pharmaceuticals Inc Cyclic amine substituted pyrimidinediamines as pkc inhibitors
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US8293753B2 (en) * 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
JP2012531454A (ja) * 2009-07-02 2012-12-10 ノバルティス アーゲー Ｐｉ３ｋ阻害剤として有用な２−カルボキサミドシクロアミノウレア類
AU2010294209A1 (en) 2009-09-10 2012-03-29 Irm Llc Ether derivatives of bicyclic heteroaryls
EP2504339A1 (en) 2009-11-25 2012-10-03 Novartis AG Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
CN102947274A (zh) 2010-06-17 2013-02-27 诺瓦提斯公司 联苯基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物
EP2582681A1 (en) 2010-06-17 2013-04-24 Novartis AG Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
BR112013009624A2 (pt) * 2010-11-08 2016-07-12 Novartis Ag uso de derivados de 2-carboxamida cicloamino ureia no tratamento de doenças dependemtes de egfr pu doenças que tenham adquirido resistência a agentes que tenham como alvo membros da família egfr
UA112539C2 (uk) 2011-03-03 2016-09-26 Новартіс Аг Спосіб одержання похідних 2-карбоксамідциклоаміносечовини
WO2012120469A1 (en) 2011-03-08 2012-09-13 Novartis Ag Fluorophenyl bicyclic heteroaryl compounds
WO2013052845A1 (en) * 2011-10-05 2013-04-11 The Board Of Trustees Of The Leland Stanford Junior University Pi-kinase inhibitors with broad spectrum anti-infective activity
US9926309B2 (en) 2011-10-05 2018-03-27 The Board Of Trustees Of The Leland Stanford Junior University Pi-kinase inhibitors with anti-infective activity
CA2865993A1 (en) * 2012-03-30 2013-10-03 Novartis Ag Compounds for use in the treatment of neuroblastoma, ewing's sarcoma or rhabdomyosarcoma
BR112014028881A2 (pt) 2012-05-23 2017-06-27 Hoffmann La Roche populações de células, banco de células, métodos de obtenção de uma população de células, métodos de identificação de um fator, métodos de seleção, métodos de fornecimento de terapia, populações de hepatócitos e método de obtenção de células
PT2897644T (pt) * 2012-09-20 2018-10-16 Novartis Ag Associação farmacêutica compreendendo um inibidor de fosfatidilinositol 3-quinase e um inibidor da aromatase
CN103232406B (zh) * 2013-04-26 2015-07-29 北京大学 一种1,3-噻唑衍生物
GB201308278D0 (en) * 2013-05-08 2013-06-12 Imp Innovations Ltd Labelled Carboxylic Acids and Their Uses in Molecular Imaging
WO2017004383A1 (en) * 2015-06-30 2017-01-05 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof
CN105294546B (zh) * 2015-10-29 2017-12-08 天津市斯芬克司药物研发有限公司 一种吡啶化合物及其制备方法
ES3010661T3 (en) 2016-02-26 2025-04-04 Univ Leland Stanford Junior Pi-kinase inhibitors with anti-infective activity
CN109111439B (zh) * 2017-06-26 2020-09-18 深圳市塔吉瑞生物医药有限公司 一种酰胺类化合物及包含该化合物的组合物及其用途
CA3115103A1 (en) * 2018-10-05 2020-04-09 Sloan-Kettering Institute For Cancer Research Pi3k inhibitors and uses thereof
AU2020241869B2 (en) 2019-03-21 2025-02-13 The Board Of Trustees Of The Leland Stanford Junior University PI4-kinase inhibitors and methods of using the same
CN120172965A (zh) * 2019-05-27 2025-06-20 君实润佳(上海)医药科技有限公司 含有稳定重同位素的酰胺官能团的化合物及其应用
CN110759900B (zh) * 2019-10-25 2021-07-30 沈阳药科大学 噻吩类化合物的制备方法和用途
IL294507A (en) 2020-01-07 2022-09-01 Disarm Therapeutics Inc Inhibitors of sarm1
TWI786777B (zh) 2020-08-24 2022-12-11 美商達薩瑪治療公司 Sarm1之抑制劑
EP4608509A1 (en) * 2022-10-28 2025-09-03 Institut National de la Santé et de la Recherche Médicale New inhibitors of phosphatidylinositol 3-kinase
CN116987072A (zh) * 2023-07-27 2023-11-03 武汉呈瑞生物医药科技有限公司 化合物及其应用
EP4643858A1 (en) * 2024-04-29 2025-11-05 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for the treatment of uterine disease

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
JPS6041077B2 (ja) 1976-09-06 1985-09-13 喜徳 喜谷 １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
US4323581A (en) 1978-07-31 1982-04-06 Johnson & Johnson Method of treating carcinogenesis
US4649146A (en) * 1983-01-31 1987-03-10 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives and pharmaceutical composition comprising the same
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
DE3427115A1 (de) * 1984-07-23 1986-03-27 Dedo Weigert Film GmbH, 8000 München Ueberwachungsgeraet
DE3703435A1 (de) 1987-02-05 1988-08-18 Thomae Gmbh Dr K Neue thiazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US4923986A (en) 1987-03-09 1990-05-08 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance K-252
US4904768A (en) 1987-08-04 1990-02-27 Bristol-Myers Company Epipodophyllotoxin glucoside 4'-phosphate derivatives
JP2766360B2 (ja) 1988-02-04 1998-06-18 協和醗酵工業株式会社 スタウロスポリン誘導体
US5229402A (en) 1988-04-15 1993-07-20 Taiho Pharmaceutical Company, Ltd. Carbamoyl-2-pyrrolidinone compounds
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
WO1993007153A1 (en) 1991-10-10 1993-04-15 Schering Corporation 4'-(n-substituted-n-oxide)staurosporine derivatives
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
EP0610433A1 (en) 1991-11-08 1994-08-17 The University Of Southern California Compositions containing k-252 compounds for potentiation of neurotrophin activity
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5948898A (en) 1992-03-16 1999-09-07 Isis Pharmaceuticals, Inc. Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
US5621100A (en) 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
US5756494A (en) 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
DE69333670T2 (de) 1992-08-31 2005-03-10 Ludwig Institute For Cancer Research Vom mage-3-gen abgeleitetes und von hla-a1 präsentiertes, isoliertes nonapeptid und dessen anwendungen
US5674867A (en) 1992-09-21 1997-10-07 Kyowa Hakko Kogyo Co., Ltd. Indolocarbazole derivatives and therapeutic method for stimulating megakaicyocyte production
HU221343B1 (en) 1992-10-28 2002-09-28 Genentech Inc Use of anti-vegf antibodies for the treatment of cancer
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
DK0708772T3 (da) 1993-07-15 2000-09-18 Minnesota Mining & Mfg Imidazo[4,5,-c]pyridin-4-aminer
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
EP1449529B1 (en) 1993-12-23 2010-01-27 Eli Lilly And Company Protein Kinase C Inhibitors
US5587459A (en) 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
EP3103799B1 (en) 1995-03-30 2018-06-06 OSI Pharmaceuticals, LLC Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
WO1997007081A2 (en) 1995-08-11 1997-02-27 Yale University Glycosylated indolocarbazole synthesis
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
WO1997021701A1 (en) 1995-12-08 1997-06-19 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
KR100447918B1 (ko) 1996-07-25 2005-09-28 동아제약주식회사 대장을포함한위장관보호작용을갖는플라본및플라바논화합물
JP4301576B2 (ja) 1996-08-02 2009-07-22 ローラス セラピューティクス インコーポレイテッド リボヌクレオチドレダクターゼのｒ１およびｒ２成分に対して指向される抗腫瘍アンチセンス配列
WO1998027108A2 (en) 1996-12-16 1998-06-25 Fujisawa Pharmaceutical Co., Ltd. New amide compounds and their use as nitric oxide synthase inhibitors
US6187797B1 (en) * 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6126965A (en) 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
ATE311884T1 (de) 1997-07-12 2005-12-15 Cancer Rec Tech Ltd Cyclin-abhängige-kinase inhibierende purinderivate
ATE257703T1 (de) 1997-10-27 2004-01-15 Takeda Chemical Industries Ltd 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
AU759226B2 (en) 1998-05-29 2003-04-10 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
ATE288904T1 (de) 1998-06-18 2005-02-15 Bristol Myers Squibb Co Durch kohlenstoff substituierte aminothiazole als inhibitoren von zyclin-abhägigen kinasen
US20030083242A1 (en) 1998-11-06 2003-05-01 Alphonse Galdes Methods and compositions for treating or preventing peripheral neuropathies
CH694589A5 (de) 1999-06-25 2005-04-15 Genentech Inc Humanisierte Anti-ErbB2-Antikörper und Behandlung mit Anti-ErbB2-Antikörpern.
CA2379035A1 (en) 1999-07-13 2001-01-18 Shiro Akinaga Staurosporin derivatives
WO2001017995A1 (en) 1999-09-10 2001-03-15 Merck & Co., Inc. Tyrosine kinase inhibitors
HK1049664B (en) 1999-11-05 2006-11-10 Genzyme Corporation Quinazoline derivatives as vegf inhibitors
BRPI0108394B8 (pt) 2000-02-15 2021-05-25 Upjohn Co inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos
JP5074653B2 (ja) 2000-03-29 2012-11-14 サイクラセル リミテッド ２−置換４−ヘテロアリール−ピリミジンおよび増殖性障害におけるその使用
WO2001079255A1 (en) 2000-04-12 2001-10-25 Genaera Corporation A process for the preparation of 7.alpha.-hydroxy 3-aminosubstituted sterols using intermediates with an unprotected 7.alpha.-hydroxy group
KR100815681B1 (ko) 2000-06-30 2008-03-20 글락소 그룹 리미티드 퀴나졸린 디토실레이트 염 화합물
AU9327501A (en) 2000-09-11 2002-03-26 Chiron Corp Quinolinone derivatives
US6677450B2 (en) 2000-10-06 2004-01-13 Bristol-Myers Squibb Company Topoisomerase inhibitors
WO2002032872A1 (fr) 2000-10-20 2002-04-25 Eisai Co., Ltd. Composes a noyau aromatique azote
WO2002057423A2 (en) 2001-01-16 2002-07-25 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
WO2002062826A1 (fr) 2001-02-07 2002-08-15 Vadim Viktorovich Novikov Procede de fabrication des peptides
EP1256578B1 (en) 2001-05-11 2006-01-11 Pfizer Products Inc. Thiazole derivatives and their use as cdk inhibitors
US20040186172A1 (en) 2001-07-02 2004-09-23 Houssam Ibrahim Oxaliplatin active substance with a very low content of oxalic acid
MXPA04001399A (es) 2001-08-13 2004-05-27 Janssen Pharmaceutica Nv Derivados de tiazolilo 2-amino-4,5-trisustituidos.
US7265134B2 (en) 2001-08-17 2007-09-04 Merck & Co., Inc. Tyrosine kinase inhibitors
KR100484504B1 (ko) 2001-09-18 2005-04-20 학교법인 포항공과대학교 쿠커비투릴 유도체를 주인 분자로서 포함하고 있는 내포화합물 및 이를 포함한 약제학적 조성물
CN100500663C (zh) 2001-09-28 2009-06-17 西克拉塞尔有限公司 作为抗增殖化合物的n-(4-(4-甲基噻唑-5-基)嘧啶-2-基)-n-苯胺
US20030134846A1 (en) 2001-10-09 2003-07-17 Schering Corporation Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors
US6927036B2 (en) 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
PE20030968A1 (es) 2002-02-28 2004-01-12 Novartis Ag Derivados de 5-feniltiazol como inhibidores de cinasas
BR0308854A (pt) 2002-03-29 2005-02-22 Chiron Corp Benzazolas substituìdas e seus usos como inibidoras de quinase raf
US6900342B2 (en) 2002-05-10 2005-05-31 Dabur India Limited Anticancer taxanes such as paclitaxel, docetaxel and their structural analogs, and a method for the preparation thereof
US6727272B1 (en) 2002-07-15 2004-04-27 Unitech Pharmaceuticals, Inc. Leflunomide analogs for treating rheumatoid arthritis
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
AU2003288956A1 (en) 2002-10-30 2004-06-07 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
US7632858B2 (en) 2002-11-15 2009-12-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
US7521062B2 (en) 2002-12-27 2009-04-21 Novartis Vaccines & Diagnostics, Inc. Thiosemicarbazones as anti-virals and immunopotentiators
EP1594524B1 (en) 2003-01-21 2012-08-15 Novartis Vaccines and Diagnostics, Inc. Use of tryptanthrin compounds for immune potentiation
GB0305152D0 (en) 2003-03-06 2003-04-09 Novartis Ag Organic compounds
EP1608369B1 (en) 2003-03-28 2013-06-26 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
AR044519A1 (es) * 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0320197D0 (en) * 2003-08-28 2003-10-01 Novartis Ag Organic compounds
CA2537841A1 (en) 2003-09-06 2005-03-24 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
ATE369349T1 (de) 2004-01-12 2007-08-15 Applied Research Systems Thiazolderivate und deren verwendung
SE0402735D0 (sv) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
AU2006251159B2 (en) 2005-05-24 2011-09-22 Merck Serono Sa Thiazole derivatives and use thereof
EP1888573A1 (en) 2005-05-24 2008-02-20 Laboratoires Serono S.A. Thiazole derivatives and use thereof
US7655446B2 (en) 2005-06-28 2010-02-02 Vertex Pharmaceuticals Incorporated Crystal structure of Rho-kinase I kinase domain complexes and binding pockets thereof
DE102005048072A1 (de) 2005-09-24 2007-04-05 Bayer Cropscience Ag Thiazole als Fungizide
US7595398B2 (en) 2005-12-12 2009-09-29 Smithkline Beecham Corporation N-(5-membered aromatic ring)-amido anti-viral compounds
GB0525671D0 (en) * 2005-12-16 2006-01-25 Novartis Ag Organic compounds
WO2007082956A1 (en) * 2006-01-23 2007-07-26 Laboratoires Serono S.A. Thiazole derivatives and use thereof
GB0610243D0 (en) * 2006-05-23 2006-07-05 Novartis Ag Organic compounds
EP2099778A2 (en) 2006-11-21 2009-09-16 Smithkline Beecham Corporation Amido anti-viral compounds
WO2008124000A2 (en) 2007-04-02 2008-10-16 Ligand Pharmaceuticals Incorporated Thiazole derivatives as androgen receptor modulator compounds
NZ581127A (en) 2007-05-25 2012-06-29 Abbott Gmbh & Co Kg Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor)
US20090004140A1 (en) 2007-06-26 2009-01-01 Yao-Ling Qiu 4-substituted pyrrolidine as anti-infectives
CA2691507C (en) 2007-07-19 2016-06-21 H. Lundbeck A/S 5-membered heterocyclic amides and related compounds
US8293753B2 (en) * 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas

Also Published As

Publication number Publication date
IL206286A0 (en) 2010-12-30
US20090163469A1 (en) 2009-06-25
JP2011506560A (ja) 2011-03-03
ZA201003928B (en) 2011-04-28
PE20091523A1 (es) 2009-10-29
CL2008003822A1 (es) 2009-06-26
EP2240475B1 (en) 2013-09-25
ES2437595T3 (es) 2014-01-13
AR069798A1 (es) 2010-02-17
CA2710122A1 (en) 2009-07-02
CO6321276A2 (es) 2011-09-20
CN101952282A (zh) 2011-01-19
ECSP10010271A (es) 2010-07-30
SMP201000096B (it) 2011-09-09
AU2008340053A1 (en) 2009-07-02
WO2009080694A1 (en) 2009-07-02
UY31545A1 (es) 2009-08-03
EP2240475A1 (en) 2010-10-20
TW200930364A (en) 2009-07-16
SMAP201000096A (it) 2010-09-10
TN2010000293A1 (en) 2011-11-11
CR11491A (es) 2010-08-05
EA201000947A1 (ru) 2011-02-28
US8940771B2 (en) 2015-01-27
NI201000107A (es) 2011-03-15
PA8809001A1 (es) 2009-07-23
BRPI0820722A2 (pt) 2015-06-16
DOP2010000183A (es) 2010-07-31
KR20100093129A (ko) 2010-08-24
MA31903B1 (fr) 2010-12-01

Similar Documents

Publication Publication Date Title
SV2010003598A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
SV2010003472A (es) Compuestos de pirazol
SV2011003853A (es) Compuestos organicos
CR11803A (es) Pirrolopiridinas como inhibidores de cinasa
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
UY31166A1 (es) Nuevos indazoles sustituidos, su preparación y su utilización en terapeutica
CR10662A (es) Compuestos de metilpiridopirimidinona
ECSP109903A (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
CU20110235A7 (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
CL2011000917A1 (es) Compuestos derivados de tioamida; sus metodos de preparacion y uso de los compuestos para el tratamiento de enfermedades endoparasitarias.
ECSP099571A (es) Derivados pirazólicos como inhibidores de la 11-beta-hsd1
ECSP088700A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
SV2009003389A (es) Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de p13k-alfa para el tratamiento del cancer
DOP2009000200A (es) Derivados de 2-amino-5,7-dihidro-6h-pirrolo[3,4-d] pimiridina como inhibidores hsp-90 para tratar el cancer
UY30476A1 (es) Noveles compuestos derivados n-sustituidos de la 3-oxoisoindolin-1-carboxamida, sus sales aceptables, composiciones farmaccuticas y aplicaciones.
ECSP099506A (es) Derivados de 2-quinolinona y 2 quinoxalinona y su utilización como agentes anti bacterianos
UY32748A (es) 2-carboxamida-cicloamino-ureas
CR11860A (es) Derivados de dibenzotiazepina y sus usos - 424
UY32954A (es) PIRIMIDINAS SUSTITUIDAS CON ADAMANTILIMINOCARBONILO COMO INHIBIDORES DE 11-ß-HSD1 826?.
NI201100035A (es) Agentes antifúngicos.
ECSP11011053A (es) [4-(1-amino-etil)-ciclohexil]-metil-aminas como antibacterianos
UY32042A (es) Compuestos de 2-aminopirimidina como potentes inhibidores de hsp-90
NI201200103A (es) NUEVOS DERIVADOS ( HETEROCICLO - TETRAHIDRO - PIRIDIN ) - ( PIPERAZINIL ) - 1 - ALCANONA Y ( HETEROCICLO - DIHIDRO - PIRROLIDIN ) - ( PIPERAZINIL ) - 1 - ALCANONA Y SU UTILIZACIÓN COMO INHIBIDORES DE p75
CY1117805T1 (el) Αντιμετωπιση οστεοπορωσης

Legal Events

Date Code Title Description
FD Lapse